Brigitte Degasperi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Brigitte Degasperi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Ingrid Walter
University of Veterinary Medicine, Vienna, Austria
2 shared publicationsAna Cristina Piroth
Klinische Abteilung für Kleintierchirurgie, Universitätsklinik für Kleintiere, Department für Kleintiere und Pferde, Vetmeduni Wien
1 shared publication- Andrea Fuchs-Baumgartinger
University of Veterinary Medicine Vienna, Vienna, Austria
1 shared publication - Andrea Klang
University of Veterinary Medicine Vienna, Vienna, Austria
1 shared publication Arlene Khachadoorian
University of Guelph, Guelph, ON, Canada
1 shared publication- Barbara C. Ruetgen
Clinical Pathology, Department of Pathobiology, University of Veterinary Medicine Vienna, Vienna, Austria
1 shared publication
Latest Publications
- Open Access
- 19 February 2025
- Published by SAGE Publications in Veterinary Pathology
- Vol. 62 (5) , 659-671
MicroRNAs in serum and tissue can differentiate splenic hemangiosarcoma from other splenic masses in dogs
Splenic masses are common in dogs and vary dramatically in their clinical behavior. Clinically, and even with histology, it can be challenging to differentiate between benign and malignant splenic masses. Hemangiosarcoma (HSA), the most common malignancy of the spleen, is a very aggressive tumor with a poor prognosis. We hypothesize that microRNAs (miRNAs) in mass tissue and serum can differentiate between HSA and other splenic masses. Fifty-nine miRNAs were investigated by reverse-transcription followed by real-time quantitative polymerase chain reaction (RT-qPCR) in serum and/or tissue from dogs with HSAs (serum n = 24 and tissue n = 17; postsplenectomy serum n = 11), lymphomas (serum n = 8 and tissue n = 11), nonangiomatous nonlymphomatous sarcomas (serum n = 6 and tissue n = 10), histiocytic sarcomas (tissue n = 4), benign splenic masses (myelolipomas, nodular hyperplasia, and hematomas; total serum n = 21 and total tissue n = 35), and normal dogs (serum n = 14 and tissue n = 7). Numerous miRNAs were differentially expressed in serum and tissue of HSA cases compared to those with other splenic masses or normal spleens. In serum, our 5-miRNA model (miR-135a-5p, miR-10a, miR-450b, miR-152-3p, and miR-126-5p) accurately classified 100% (24/24) of dogs with HSA from normal dogs and those with a benign splenic mass (recall = 1 for HSA). The overall accuracy of the model was 86%. In HSA and benign splenic mass tissues, our 3-miRNA model (miR-126-5p, miR-502-3p, and miR-452-5p) accurately classified 96% of the cases. This study demonstrates the utility of miRNA models in serum and tissue for screening and diagnosis of HSA in dogs. Future studies include the evaluation of prospective and prediagnosis serum samples.
- 19 February 2025
- Published by SAGE Publications in Veterinary Pathology
- Vol. 62 (5) , 659-671
Open AccessMicroRNAs in serum and tissue can differentiate splenic hemangiosarcoma from other splenic masses in dogs
Splenic masses are common in dogs and vary dramatically in their clinical behavior. Clinically, and even with histology, it can be challenging to differentiate between benign and malignant splenic masses. Hemangiosarcoma (HSA), the most common malignancy of the spleen, is a very aggressive tumor with a poor prognosis. We hypothesize that microRNAs (miRNAs) in mass tissue and serum can differentiate between HSA and other splenic masses. Fifty-nine miRNAs were investigated by reverse-transcription followed by real-time quantitative polymerase chain reaction (RT-qPCR) in serum and/or tissue from dogs with HSAs (serum n = 24 and tissue n = 17; postsplenectomy serum n = 11), lymphomas (serum n = 8 and tissue n = 11), nonangiomatous nonlymphomatous sarcomas (serum n = 6 and tissue n = 10), histiocytic sarcomas (tissue n = 4), benign splenic masses (myelolipomas, nodular hyperplasia, and hematomas; total serum n = 21 and total tissue n = 35), and normal dogs (serum n = 14 and tissue n = 7). Numerous miRNAs were differentially expressed in serum and tissue of HSA cases compared to those with other splenic masses or normal spleens. In serum, our 5-miRNA model (miR-135a-5p, miR-10a, miR-450b, miR-152-3p, and miR-126-5p) accurately classified 100% (24/24) of dogs with HSA from normal dogs and those with a benign splenic mass (recall = 1 for HSA). The overall accuracy of the model was 86%. In HSA and benign splenic mass tissues, our 3-miRNA model (miR-126-5p, miR-502-3p, and miR-452-5p) accurately classified 96% of the cases. This study demonstrates the utility of miRNA models in serum and tissue for screening and diagnosis of HSA in dogs. Future studies include the evaluation of prospective and prediagnosis serum samples.
- Open Access
- 25 September 2024
- Published by SAGE Publications in Veterinary Pathology
- Vol. 62 (2) , 187-194
Feline eosinophilic sclerosing fibroplasia associated with T-/natural killer-cell lymphoma
Feline eosinophilic sclerosing fibroplasia (FESF) is a proliferative, inflammatory disease of the gastrointestinal tract and other sites, uncommonly diagnosed in the cat. This entity of uncertain etiology typically presents as a progressive mass lesion, mimicking a neoplastic process. In this case series, we present 17 cases of FESF associated with intralesional lymphoma. Histologic and immunohistochemical characterization of this unique lymphoma revealed that the neoplastic lymphocytes were immunopositive for CD56 and/ or CD3, suggesting a natural killer cell, natural killer T-cell, or T-cell origin. This case series represents the first description of this lymphoma subtype, for which the term eosinophilic sclerosing lymphoma is proposed.
- 25 September 2024
- Published by SAGE Publications in Veterinary Pathology
- Vol. 62 (2) , 187-194
Open AccessFeline eosinophilic sclerosing fibroplasia associated with T-/natural killer-cell lymphoma
Feline eosinophilic sclerosing fibroplasia (FESF) is a proliferative, inflammatory disease of the gastrointestinal tract and other sites, uncommonly diagnosed in the cat. This entity of uncertain etiology typically presents as a progressive mass lesion, mimicking a neoplastic process. In this case series, we present 17 cases of FESF associated with intralesional lymphoma. Histologic and immunohistochemical characterization of this unique lymphoma revealed that the neoplastic lymphocytes were immunopositive for CD56 and/ or CD3, suggesting a natural killer cell, natural killer T-cell, or T-cell origin. This case series represents the first description of this lymphoma subtype, for which the term eosinophilic sclerosing lymphoma is proposed.
- 26 April 2021
- Published by Georg Thieme Verlag KG in Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere
- Vol. 49 (02) , 134-141
Intrapelvines Leiomyom als Ursache für gleichzeitige Darm- und Harntraktobstruktion bei einem Hund
Zusammenfassung: Eine 8-jährige, kastrierte Mischlingshündin wurde wegen fehlenden Harn- und Kotabsatzes vorgestellt. Bei der rektalen Untersuchung ließ sich eine glatte, kugelige, derb-elastische Masse palpieren. Die Blutuntersuchung ergab eine 6-fach erhöhte Serumaktivität der Laktatdehydrogenase. Die Befunde von Röntgen, Ultraschall und Computertomografie lieferten den Verdacht eines Leiomyoms. Ein in Sedation unter Ultraschallkontrolle entnommenes Feinnadelaspirat war nicht diagnostisch. Bei der Laparotomie konnte die Masse extraluminal am Übergang vom Colon descendens zum Rektum lokalisiert und unter Schonung des Darms in toto reseziert werden. Die histopathologischen Befunde und immunhistochemischen Färbungen bestätigten die Verdachtsdiagnose eines Leiomyoms. Die Hündin konnte postoperativ Harn und Kot absetzen und präsentierte sich nach 6 Monaten weiterhin unauffällig. Sonografisch ergab sich kein Hinweis auf ein Rezidiv und die Aktivität der Laktatdehydrogenase war nur mehr marginal erhöht.
- 26 April 2021
- Published by Georg Thieme Verlag KG in Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere
- Vol. 49 (02) , 134-141
Intrapelvines Leiomyom als Ursache für gleichzeitige Darm- und Harntraktobstruktion bei einem Hund
Zusammenfassung: Eine 8-jährige, kastrierte Mischlingshündin wurde wegen fehlenden Harn- und Kotabsatzes vorgestellt. Bei der rektalen Untersuchung ließ sich eine glatte, kugelige, derb-elastische Masse palpieren. Die Blutuntersuchung ergab eine 6-fach erhöhte Serumaktivität der Laktatdehydrogenase. Die Befunde von Röntgen, Ultraschall und Computertomografie lieferten den Verdacht eines Leiomyoms. Ein in Sedation unter Ultraschallkontrolle entnommenes Feinnadelaspirat war nicht diagnostisch. Bei der Laparotomie konnte die Masse extraluminal am Übergang vom Colon descendens zum Rektum lokalisiert und unter Schonung des Darms in toto reseziert werden. Die histopathologischen Befunde und immunhistochemischen Färbungen bestätigten die Verdachtsdiagnose eines Leiomyoms. Die Hündin konnte postoperativ Harn und Kot absetzen und präsentierte sich nach 6 Monaten weiterhin unauffällig. Sonografisch ergab sich kein Hinweis auf ein Rezidiv und die Aktivität der Laktatdehydrogenase war nur mehr marginal erhöht.